3-hydroxybutyric acid has been researched along with Heart Failure in 21 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine whether the circulating substrate mix may be related to the incidence of heart failure (HF) and cardiovascular (CV) mortality and how it is altered by canagliflozin treatment." | 5.51 | Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). ( Baldi, S; Ferrannini, E; Figtree, GA; Hansen, MK; Mahaffey, KW; Neal, B; Perkovic, V; Rosenthal, N; Scozzaro, T; Shaw, W; Tesfaye, F; Tsimihodimos, V, 2022) |
| "These results suggested that in patients with heart failure, MEE elevation was associated with significant changes in serum metabolomics profiles, especially the concentration of 3-hydroxybutyrate, acetone and succinate." | 3.80 | 1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients. ( Du, Z; Huang, Y; Lai, W; Ren, H; Shen, A; Su, L; Wang, P; Xie, Z; Xu, D; Zeng, Q, 2014) |
| "Treatment with empagliflozin did not affect ketone body concentrations in patients with acute HF." | 3.30 | Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial. ( Beusekamp, JC; Boorsma, EM; Connelly, MA; Damman, K; DE-Boer, RA; Dullaart, RPF; VAN-DER-Meer, P; VAN-Veldhuisen, DJ; Voorrips, SN; Voors, AA; Westenbrink, BD, 2023) |
| " Study 2: In a dose-response study, 8 HFrEF patients were examined at increasing 3-OHB infusion rates." | 2.90 | Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. ( Bøtker, HE; Eiskjaer, H; Frøkiær, J; Gormsen, LC; Hansson, NH; Harms, HJ; Jespersen, NR; Lassen, TR; Mellemkjaer, S; Møller, N; Nielsen, R; Pryds, K; Sorensen, J; Tolbod, LP; Wiggers, H, 2019) |
| "These data suggest that severe CHF is a ketosis-prone state." | 1.30 | Heart failure ketosis. ( Härkönen, M; Koskinen, P; Kupari, M; Lommi, J; Näveri, H, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 12 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Pietschner, R | 1 |
| Kolwelter, J | 1 |
| Bosch, A | 1 |
| Striepe, K | 1 |
| Jung, S | 1 |
| Kannenkeril, D | 1 |
| Ott, C | 1 |
| Schiffer, M | 1 |
| Achenbach, S | 1 |
| Schmieder, RE | 1 |
| Ferrannini, E | 1 |
| Baldi, S | 1 |
| Scozzaro, T | 1 |
| Tsimihodimos, V | 1 |
| Tesfaye, F | 1 |
| Shaw, W | 1 |
| Rosenthal, N | 1 |
| Figtree, GA | 1 |
| Neal, B | 1 |
| Mahaffey, KW | 1 |
| Perkovic, V | 1 |
| Hansen, MK | 1 |
| Voorrips, SN | 1 |
| Boorsma, EM | 1 |
| Beusekamp, JC | 1 |
| DE-Boer, RA | 1 |
| Connelly, MA | 2 |
| Dullaart, RPF | 2 |
| VAN-DER-Meer, P | 1 |
| VAN-Veldhuisen, DJ | 1 |
| Voors, AA | 1 |
| Damman, K | 1 |
| Westenbrink, BD | 2 |
| Matsuura, TR | 2 |
| Puchalska, P | 1 |
| Crawford, PA | 2 |
| Kelly, DP | 3 |
| Berg-Hansen, K | 1 |
| Christensen, KH | 1 |
| Gopalasingam, N | 1 |
| Nielsen, R | 2 |
| Eiskjær, H | 1 |
| Møller, N | 2 |
| Birkelund, T | 1 |
| Christensen, S | 1 |
| Wiggers, H | 2 |
| Lee, YK | 1 |
| Oh, TJ | 1 |
| Lee, JI | 1 |
| Choi, BY | 1 |
| Cho, HC | 1 |
| Jang, HC | 1 |
| Choi, SH | 1 |
| Zhang, X | 1 |
| Wang, N | 1 |
| Fu, P | 1 |
| An, Y | 1 |
| Sun, F | 1 |
| Wang, C | 1 |
| Han, X | 1 |
| Zhang, Y | 2 |
| Yu, X | 1 |
| Liu, Y | 1 |
| Nambu, H | 1 |
| Takada, S | 1 |
| Fukushima, A | 1 |
| Matsumoto, J | 1 |
| Kakutani, N | 1 |
| Maekawa, S | 1 |
| Shirakawa, R | 1 |
| Nakano, I | 1 |
| Furihata, T | 1 |
| Katayama, T | 1 |
| Yamanashi, K | 1 |
| Obata, Y | 1 |
| Saito, A | 1 |
| Yokota, T | 1 |
| Kinugawa, S | 1 |
| Corbi, G | 1 |
| Conti, V | 1 |
| Troisi, J | 1 |
| Colucci, A | 1 |
| Manzo, V | 1 |
| Di Pietro, P | 1 |
| Calabrese, MC | 1 |
| Carrizzo, A | 1 |
| Vecchione, C | 1 |
| Ferrara, N | 1 |
| Filippelli, A | 1 |
| Soto-Mota, A | 1 |
| Norwitz, NG | 1 |
| Clarke, K | 1 |
| Nakamura, M | 1 |
| Odanovic, N | 1 |
| Nakada, Y | 1 |
| Dohi, S | 1 |
| Zhai, P | 1 |
| Ivessa, A | 1 |
| Yang, Z | 1 |
| Abdellatif, M | 1 |
| Sadoshima, J | 1 |
| Deng, Y | 1 |
| Xie, M | 1 |
| Li, Q | 1 |
| Xu, X | 1 |
| Ou, W | 1 |
| Xiao, H | 1 |
| Yu, H | 1 |
| Zheng, Y | 1 |
| Liang, Y | 1 |
| Jiang, C | 1 |
| Chen, G | 1 |
| Du, D | 1 |
| Zheng, W | 1 |
| Wang, S | 1 |
| Gong, M | 1 |
| Chen, Y | 1 |
| Tian, R | 1 |
| Li, T | 1 |
| Flores-Guerrero, JL | 1 |
| Otvos, JD | 1 |
| Groothof, D | 1 |
| Shalaurova, I | 1 |
| Garcia, E | 1 |
| Navis, G | 1 |
| de Boer, RA | 1 |
| Bakker, SJL | 1 |
| Voros, G | 1 |
| Ector, J | 1 |
| Garweg, C | 1 |
| Droogne, W | 1 |
| Van Cleemput, J | 1 |
| Peersman, N | 1 |
| Vermeersch, P | 1 |
| Janssens, S | 1 |
| Horton, JL | 1 |
| Davidson, MT | 1 |
| Kurishima, C | 1 |
| Vega, RB | 1 |
| Powers, JC | 1 |
| Petucci, C | 1 |
| Lewandowski, ED | 1 |
| Muoio, DM | 2 |
| Recchia, FA | 1 |
| Ho, KL | 1 |
| Zhang, L | 1 |
| Wagg, C | 1 |
| Al Batran, R | 1 |
| Gopal, K | 1 |
| Levasseur, J | 1 |
| Leone, T | 1 |
| Dyck, JRB | 1 |
| Ussher, JR | 1 |
| Lopaschuk, GD | 1 |
| Gormsen, LC | 1 |
| Tolbod, LP | 1 |
| Hansson, NH | 1 |
| Sorensen, J | 1 |
| Harms, HJ | 1 |
| Frøkiær, J | 1 |
| Eiskjaer, H | 1 |
| Jespersen, NR | 1 |
| Mellemkjaer, S | 1 |
| Lassen, TR | 1 |
| Pryds, K | 1 |
| Bøtker, HE | 1 |
| Stryeck, S | 1 |
| Gastrager, M | 1 |
| Degoricija, V | 1 |
| Trbušić, M | 1 |
| Potočnjak, I | 1 |
| Radulović, B | 1 |
| Pregartner, G | 1 |
| Berghold, A | 1 |
| Madl, T | 1 |
| Frank, S | 1 |
| Du, Z | 1 |
| Shen, A | 1 |
| Huang, Y | 1 |
| Su, L | 1 |
| Lai, W | 1 |
| Wang, P | 1 |
| Xie, Z | 2 |
| Zeng, Q | 1 |
| Ren, H | 1 |
| Xu, D | 1 |
| Lommi, J | 1 |
| Koskinen, P | 1 |
| Näveri, H | 1 |
| Härkönen, M | 1 |
| Kupari, M | 1 |
| Bleiberg, B | 1 |
| Steinberg, JJ | 1 |
| Katz, SD | 1 |
| Wexler, J | 1 |
| LeJemtel, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure[NCT03128528] | Phase 2 | 84 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus[NCT01032629] | Phase 3 | 4,330 participants (Actual) | Interventional | 2009-12-09 | Completed | ||
| Evaluation of the Safety and Tolerability of Exogenous Ketosis Induced by Free Beta-hydroxybutyrate.[NCT05584371] | 30 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | |||
| Comparison Between Endogenous and Exogenous Ketosis in Patients With Non-ischemic Chronic Heart Failure With Reduced Ejection Fraction[NCT04921293] | 18 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| Functional and Metabolic Effects of Ketone Bodies on Human Atrial Tissue in Patients With and Without Heart Failure[NCT04379934] | 40 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | |||
| Physiological Effects of Lactate in Individuals With Chronic Heart Failure[NCT06121323] | 12 participants (Anticipated) | Interventional | 2023-11-22 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m^2) = 175 * (serum creatinine) ^ 1.154 * (Age) ^-0.203 *(0.742 if female) * (1.21 if Black). (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Placebo | -5.23 |
| Canagliflozin 100 mg | -3.55 |
| Canagliflozin 300 mg | -3.98 |
Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Millimoles per liter (mmol/L) (Least Squares Mean) |
|---|---|
| Placebo | 0.16 |
| Canagliflozin 100 mg | -0.42 |
| Canagliflozin 300 mg | -0.57 |
Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | HbA1c (%) (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Canagliflozin 100 mg | -0.26 |
| Canagliflozin 300 mg | -0.31 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Percentage of HOMA2 (Least Squares Mean) |
|---|---|
| Placebo | 4.02 |
| Canagliflozin 100 mg | 6.82 |
| Canagliflozin 300 mg | 8.09 |
Change from baseline in LDL-C to HDL-C ratio was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.04 |
| Canagliflozin 100 mg | -0.02 |
| Canagliflozin 300 mg | 0.00 |
A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Picomole per milli international units (Least Squares Mean) |
|---|---|
| Placebo | 0.70 |
| Canagliflozin 100 mg | 0.67 |
| Canagliflozin 300 mg | 1.03 |
Change from baseline in triglycerides levels was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.05 |
| Canagliflozin 100 mg | 0.13 |
| Canagliflozin 300 mg | 0.09 |
Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine. (NCT01032629)
Timeframe: Baseline and End of treatment (approximately 338 weeks)
| Intervention | Milligram per gram (mg/g) (Geometric Mean) |
|---|---|
| Placebo | 29.30 |
| Canagliflozin 100 mg | 25.50 |
| Canagliflozin 300 mg | 24.47 |
MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented. (NCT01032629)
Timeframe: Up to approximately 8 years
| Intervention | Events per 1000 patient-year (Number) |
|---|---|
| Placebo | 30.36 |
| Canagliflozin 100 mg | 28.41 |
| Canagliflozin 300 mg | 25.37 |
| Canagliflozin (Total) | 26.89 |
Percent change from baseline in body weight was assessed at the end of treatment. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.50 |
| Canagliflozin 100 mg | -3.47 |
| Canagliflozin 300 mg | -4.12 |
Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to [>=] 30 milligram per gram (mg/g) and less than or equal to <= 300 mg/g) or macroalbuminuria (ACR of >300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed. (NCT01032629)
Timeframe: End of treatment (approximately 338 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 24.0 |
| Canagliflozin 100 mg | 20.2 |
| Canagliflozin 300 mg | 18.3 |
Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | mmol/L (Least Squares Mean) | ||
|---|---|---|---|
| Cholesterol (change at EOT) | HDL-C (change at EOT) | LDL-C (change at EOT) | |
| Canagliflozin 100 mg | 0.11 | 0.04 | 0.04 |
| Canagliflozin 300 mg | 0.16 | 0.05 | 0.10 |
| Placebo | -0.07 | -0.01 | -0.07 |
Change from baseline in systolic blood pressure and diastolic blood pressure was assessed. (NCT01032629)
Timeframe: Baseline and end of treatment (approximately 338 weeks)
| Intervention | Millimeter of mercury (mmHg) (Least Squares Mean) | |
|---|---|---|
| SBP(Change at end of treatment) | DBP (Change at end of treatment) | |
| Canagliflozin 100 mg | -4.91 | -3.70 |
| Canagliflozin 300 mg | -6.49 | -4.51 |
| Placebo | -1.96 | -2.88 |
2 reviews available for 3-hydroxybutyric acid and Heart Failure
| Article | Year |
|---|---|
Ketones and the Heart: Metabolic Principles and Therapeutic Implications.
Topics: 3-Hydroxybutyric Acid; Epigenesis, Genetic; Heart Failure; Humans; Ketone Bodies; Ketones; Ketosis | 2023 |
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
5 trials available for 3-hydroxybutyric acid and Heart Failure
| Article | Year |
|---|---|
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Topics: 3-Hydroxybutyric Acid; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Chronic Disease; Doub | 2021 |
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
Topics: 3-Hydroxybutyric Acid; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; G | 2022 |
Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Heart Failure; Humans; Ketone Bodies | 2023 |
Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock: A Randomized, Controlled, Double-Blind Trial.
Topics: 3-Hydroxybutyric Acid; Cross-Over Studies; Heart Failure; Hemodynamics; Humans; Ketone Bodies; Keton | 2023 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acetates; Aged; Carbon Radioisotopes; Chronic Disease; Female; Heart Failure; | 2019 |
14 other studies available for 3-hydroxybutyric acid and Heart Failure
| Article | Year |
|---|---|
Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model.
Topics: 3-Hydroxybutyric Acid; Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diet | 2023 |
Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate-activated Citrate Synthase.
Topics: 3-Hydroxybutyric Acid; Acetyl Coenzyme A; Animals; Citrate (si)-Synthase; Heart Failure; Humans; Mal | 2023 |
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Disease Models, | 2020 |
Cardiac Rehabilitation Increases SIRT1 Activity and
Topics: 3-Hydroxybutyric Acid; Aged; Antioxidants; Cardiac Rehabilitation; Exercise; Heart Failure; Humans; | 2019 |
Dietary carbohydrates restriction inhibits the development of cardiac hypertrophy and heart failure.
Topics: 3-Hydroxybutyric Acid; Animal Feed; Animals; Cells, Cultured; Diet, High-Protein Low-Carbohydrate; D | 2021 |
Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF.
Topics: 3-Hydroxybutyric Acid; 3T3 Cells; Acetyl Coenzyme A; Acetylation; Aged; Animals; Anti-Inflammatory A | 2021 |
Association of beta-hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort.
Topics: 3-Hydroxybutyric Acid; Adult; Aged; Cohort Studies; Female; Heart Failure; Humans; Male; Middle Aged | 2021 |
Increased Cardiac Uptake of Ketone Bodies and Free Fatty Acids in Human Heart Failure and Hypertrophic Left Ventricular Remodeling.
Topics: 3-Hydroxybutyric Acid; Adaptation, Physiological; Aged; Aged, 80 and over; Aortic Valve Stenosis; Bi | 2018 |
The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense.
Topics: 3-Hydroxybutyric Acid; Animals; Disease Models, Animal; Disease Progression; Dogs; Energy Metabolism | 2019 |
Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.
Topics: 3-Hydroxybutyric Acid; Acetylation; Acyl-CoA Dehydrogenase, Long-Chain; Adaptation, Physiological; A | 2019 |
Serum Concentrations of Citrate, Tyrosine, 2- and 3- Hydroxybutyrate are Associated with Increased 3-Month Mortality in Acute Heart Failure Patients.
Topics: 3-Hydroxybutyric Acid; Acute Disease; Aged; Aged, 80 and over; Biomarkers; Citric Acid; Comorbidity; | 2019 |
1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients.
Topics: 3-Hydroxybutyric Acid; Acetone; Adult; Aged; Aged, 80 and over; Energy Metabolism; Female; Heart Fai | 2014 |
Heart failure ketosis.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Heart Failure; Humans; Hydroxybutyrates; Ketone Bodies; Ketosi | 1997 |
Determination of plasma lactic acid concentration and specific activity using high-performance liquid chromatography.
Topics: 3-Hydroxybutyric Acid; Acetates; Chromatography, High Pressure Liquid; Heart Failure; Humans; Hydrox | 1991 |